Prostate Cancer
Show only recruiting trials?

ARROW
Study of I-131-1095 Radiotherapy in Combination With Enzalutamide in Patients With Metastatic Castration resistant Prostate Cancer Who Are Chemotherapy Naive and Have Progressed on Abiraterone (ARROW)
Status
Recruiting
JCP
Arrow
NCT
NCT03939689

C3441021 | TALAPRO-2
Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC (TALAPRO-2)
Status
Recruiting
JCP
JCP061
NCT
NCT03395197

GURC | 212082PCR4049
A Study of Participants With Advanced Prostate Cancer in Canada (GURC)
Status
Recruiting
JCP
JCP048
NCT
NCT03501173

IND223
A Phase II Study of Palbociclib, A CDK4/6 Inhibitor, in Patients With Metastatic Castration-Resistant Prostate Cancer
Status
Recruiting
JCP
IND223
NCT
NCT02905318

IND234
Prostate Cancer Biomarker Enrichment and Treatment Selection (PC-BETS) Study
Status
Recruiting
JCP
IND234
NCT
NCT03385655

SPLASH
Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment (SPLASH)
Status
Recruiting
JCP
JCP097
NCT
NCT04647526

3TMPO
Triple-tracer Molecular Imaging Using 18F-FDG, 68Ga-PSMA and 68Ga-OCTREOTATE to Characterize Metastatic Castration-resistant Prostate Cancer (mCRPC) and Evaluate Eligibility for Radionuclide Therapies
Status
Opening Soon
JCP
JCP093
NCT
NCT04000776

ARCHES | 9785-CL-0335
A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) (ARCHES)
Status
Closed to Accrual
JCP
JCP011
NCT
NCT02677896

CO39303
Ipatasertib Plus Abiraterone Plus Prednisone / Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone / Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer (IPATential150)
Status
Closed to Accrual
JCP
JCP022
NCT
NCT03072238

PSMA-617-01
Study of 177Lu-PSMA-617 in Metastatic Castrate-Resistant Prostate Cancer (VISION)
Status
Closed to Accrual
JCP
PSMA-617-01
NCT
NCT03511664
Filter Clinical Trials by:
Biomarkers: